The use of Yttrium-90 Ibritumomab Tiuxetan (<sup>90</sup>Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation

Wojciech Jurczak; Elżbieta Kisiel; Joanna Sawczuk-Chabin; Piotr Centkowski; Wanda Knopińska-Posłuszny; Omeir Khan

doi:10.5114/wo.2015.50012

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2015
vol. 19

Send email

Copy url:

abstract:

Original paper

The use of Yttrium-90 Ibritumomab Tiuxetan (⁹⁰Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation

Wojciech Jurczak

,

Elżbieta Kisiel

,

Joanna Sawczuk-Chabin

,

Piotr Centkowski

,

Wanda Knopińska-Posłuszny

,

Omeir Khan

Contemp Oncol (Pozn) 2015; 19 (1): 43–47

DOI: https://doi.org/10.5114/wo.2015.50012

Online publish date: 2015/03/26

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Jurczak W, Kisiel E, Sawczuk-Chabin J, Centkowski P, Knopińska-Posłuszny W, Khan O. The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. Contemporary Oncology/Współczesna Onkologia. 2015;19(1):43-47. doi:10.5114/wo.2015.50012.

APA

Jurczak, W., Kisiel, E., Sawczuk-Chabin, J., Centkowski, P., Knopińska-Posłuszny, W.,  & Khan, O. (2015). The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. Contemporary Oncology/Współczesna Onkologia, 19(1), 43-47. https://doi.org/10.5114/wo.2015.50012

Chicago

Jurczak, Wojciech, Elżbieta Kisiel, Joanna Sawczuk-Chabin, Piotr Centkowski, Wanda Knopińska-Posłuszny,  and Omeir Khan. 2015. "The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation". Contemporary Oncology/Współczesna Onkologia 19 (1): 43-47. doi:10.5114/wo.2015.50012.

Harvard

Jurczak, W., Kisiel, E., Sawczuk-Chabin, J., Centkowski, P., Knopińska-Posłuszny, W.,  and Khan, O. (2015). The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. Contemporary Oncology/Współczesna Onkologia, 19(1), pp.43-47. https://doi.org/10.5114/wo.2015.50012

MLA

Jurczak, Wojciech et al. "The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation." Contemporary Oncology/Współczesna Onkologia, vol. 19, no. 1, 2015, pp. 43-47. doi:10.5114/wo.2015.50012.

Vancouver

Jurczak W, Kisiel E, Sawczuk-Chabin J, Centkowski P, Knopińska-Posłuszny W, Khan O. The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. Contemporary Oncology/Współczesna Onkologia. 2015;19(1):43-47. doi:10.5114/wo.2015.50012.

PlumX metrics:

Aim of the study: To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan (⁹⁰Y-IT) as a consolidation therapy in the management of DLBCL.

Material and methods: Patients with primary refractory or high-risk DLBCL (n = 18), ineligible for autologous stem-cell transplantation, were included in a retrospective study performed at three centers by the Polish Lymphoma Research Group (PLRG). All patients (mean age 61, range 35–82) either didn’t achieve a complete response or didn’t complete the scheduled therapy due to its complications. Response rates (CR, PR, SD, PD) according to Cheson criteria, overall survival (OS), progression-free survival (PFS) and adverse effects of radioimmunotherapy were analyzed.

Results: Consolidation radioimmunotherapy increased the CR rate from 38% (n = 7) to 82% (n = 15). One patient remained in PR, one patient remained in SD, while one patient remained in PD. During a median follow-up of five years, 11 patients (62%) were alive with no recurrence, 4 patients (22%) were alive with relapse while 3 patients (16%) died. There was no statistically significant difference in PFS between those in CR and those in PR before ⁹⁰Y-IT.

Conclusions: Radioimmunotherapy is an effective consolidation therapy for high risk/refractory DLBCL patients and worthy of further investigation in prospective trials.

keywords:

The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation

Wojciech Jurczak , Elżbieta Kisiel , Joanna Sawczuk-Chabin , Piotr Centkowski , Wanda Knopińska-Posłuszny , Omeir Khan

diffuse large B-cell lymphoma, radioimmunotherapy, Yttrium-90 Ibritumomab Tiuxetan, consolidation

The use of Yttrium-90 Ibritumomab Tiuxetan (⁹⁰Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation

Wojciech Jurczak

,

Elżbieta Kisiel

,

Joanna Sawczuk-Chabin

,

Piotr Centkowski

,

Wanda Knopińska-Posłuszny

,

Omeir Khan